Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité — Universitatsmedizin Berlin, discusses a trial of secondary cytoreductive surgery in patients with ovarian cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

Sehouli says that surgery is the cornerstone of primary treatment for ovarian cancer, followed by subsequent chemotherapy with platinum combinations. The role of surgery in the relapsed setting is not as defined though, Sehouli adds.

In a randomized controlled phase III study, secondary cytoreductive surgery was evaluated in patients with platinum-sensitive recurrent ovarian cancer.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Ovarian Cancer

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

ESGO Congress

Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses a trial of secondary cytoreductive surgery in patients with ovarian cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

Dr. Sehouli Discusses Trial of Secondary Cytoreductive Surgery in Ovarian Cancer